| Literature DB >> 34123842 |
Yuki Nakamura1, Masahiro Takada1, Michiko Imamura2, Akane Higami1, He Jiaxi1, Makoto Fujino1, Rie Nakagawa1, Yukiko Inagaki1, Yoshiaki Matsumoto1, Kosuke Kawaguchi1, Masahiro Kawashima1, Eiji Suzuki1, Masakazu Toi1.
Abstract
BACKGROUND: The Medical Imaging Projection System (MIPS) projects indocyanine green (ICG) fluorescence images directly on the surgical field using a projection mapping technique. We conducted an observational study of sentinel lymph node (SLN) biopsy using the prototype MIPS; we found a high identification rate. However, the number of SLN-positive cases was small, and the sensitivity could not be evaluated. The aim of this study was to investigate the clinical usefulness of the MIPS assisted ICG fluorescence method using commercially available equipment.Entities:
Keywords: breast cancer; identification rate; indocyanine green fluorescence method; projection mapping; sentinel lymph node biopsy
Year: 2021 PMID: 34123842 PMCID: PMC8187896 DOI: 10.3389/fonc.2021.674419
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1The Medical Imaging Projection System (MIPS). Photograph of the commercial-type MIPS used in this study.
Figure 2Intraoperative photograph of using the MIPS. (A) Operator can confirm the ICG fluorescence image directly in the surgical field. (B) Both the operator and assistant can share the ICG fluorescence image in the surgical field.
Patient and tumor characteristics.
| Factors | N | % |
|---|---|---|
| All procedures | 84 | |
| Age, median (range) | 59 (35–84) | |
| Body Mass Index, median (range) | 21.1 (16.4-32.6) | |
| Tumor stage | ||
| Tis | 15 | 18 |
| T1a | 6 | 7 |
| T1b | 10 | 12 |
| T1c | 30 | 36 |
| T2 | 21 | 25 |
| T3 | 1 | 1 |
| Histology | ||
| Ductal Carcinoma in situ | 15 | 18 |
| Invasive carcinoma (no special type) | 60 | 71 |
| Invasive lobular carcinoma | 5 | 6 |
| Others | 4 | 5 |
| Subtype | ||
| Hormone-receptor-positive and HER2-negative | 53 | 63 |
| Hormone-receptor-positive and HER2-positive | 6 | 7 |
| Hormone-receptor-negative and HER2-positive | 2 | 2 |
| Triple negative | 8 | 10 |
| Unknown | 15 | 18 |
| Histological grade | ||
| 1 | 16 | 19 |
| 2 | 30 | 36 |
| 3 | 23 | 27 |
| Unknown | 15 | 18 |
| Preoperative systemic therapy | ||
| Yes | 11 | 13 |
| No | 73 | 87 |
| Combined use of radioisotope method | ||
| Yes | 60 | 71 |
| No | 24 | 29 |
HER2, human epidermal growth factor receptor 2.
The number of SLNs among cases using MIPS and RI.
| SLN biopsy procedures | Identified SLNs (total N=185) | Positive SLNs(total N=9) |
|---|---|---|
| MIPS and RI | 90 | 8 |
| MIPS only | 91 | 1 |
| RI only | 2 | 0 |
| Neither MIPS nor RI | 2 | 0 |
SLN, sentinel lymph node; MIPS, medical imaging projection system; RI, radioisotope.
Number of SLNs identified by the MIPS according to patient characteristics.
| Characteristics | N | Median | Range | P value |
|---|---|---|---|---|
| All procedures | 84 | 3 | 1-6 | |
| BMI | ||||
| <22 kg/m2 | 46 | 3 | 1-6 | 0.09 |
| ≧22 kg/m2 | 38 | 2.5 | 1-5 | |
| PST | ||||
| Yes | 11 | 3 | 2-5 | 0.75 |
| No | 73 | 3 | 1-6 |
SLN, sentinel lymph node; BMI, body mass index; PST, preoperative systemic therapy.
Results of the questionnaire survey for doctors with an experience in using MIPS.
| Questionnaire survey | Number of ‘yes’ | % (total 13) |
|---|---|---|
| Which do you consider to be a clinical advantage of MIPS? | ||
| Operators can perform the procedures easily by confirming the ICG fluorescence image directly in the surgical field. | 9 | 69 |
| Operators can perform the surgery without disruption of the surgical workflow since MIPS does not require operating lights. | 7 | 54 |
| Operators can operate smoothly without holding the NIR camera. | 8 | 62 |
| The operator and assistant can communicate with each other easily due to the possibility of sharing the ICG fluorescence image. | 8 | 62 |
| Do you feel the MIPS leads to shorter surgery duration? | ||
| Yes | 5 | 38 |
| No | 4 | 31 |
| Neither | 4 | 31 |
MIPS, medical imaging system projection system; ICG, indocyanine green.